Published in N Engl J Med on May 08, 2003
Busulfan and Melphalan Conditioning in Multiple Myeloma | NCT01923935
Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM | NCT03706547
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Multiple myeloma. Blood (2008) 5.88
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol (2009) 5.73
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet (2010) 5.04
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol (2010) 3.09
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol (2011) 2.78
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood (2011) 2.54
Treatment of multiple myeloma. Nat Rev Clin Oncol (2011) 2.46
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol (2008) 2.30
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
Treatment of myeloma: cure vs control. Mayo Clin Proc (2008) 1.98
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia (2009) 1.97
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med (2015) 1.92
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant (2013) 1.88
Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol (2009) 1.88
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood (2009) 1.86
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood (2007) 1.83
Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant (2013) 1.80
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood (2011) 1.76
Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. J Clin Oncol (2010) 1.66
Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma (2009) 1.63
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood (2008) 1.59
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica (2010) 1.58
Approach to the treatment of multiple myeloma: a clash of philosophies. Blood (2011) 1.57
Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. Biol Blood Marrow Transplant (2014) 1.55
Religious struggle and religious comfort in response to illness: health outcomes among stem cell transplant patients. J Behav Med (2005) 1.45
Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol (2008) 1.44
Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results-Medicare Database. Biol Blood Marrow Transplant (2015) 1.42
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther (2009) 1.40
Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood (2008) 1.40
Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells. Clin Cancer Res (2009) 1.38
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol (2012) 1.35
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica (2011) 1.32
Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica (2011) 1.31
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant (2009) 1.31
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood (2010) 1.23
Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer (2011) 1.20
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood (2005) 1.19
Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk Res (2009) 1.16
Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant (2009) 1.14
Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. J Cancer Res Clin Oncol (2007) 1.13
The Arkansas approach to therapy of patients with multiple myeloma. Best Pract Res Clin Haematol (2007) 1.09
Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood (2005) 1.09
Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther (2009) 1.09
Advances in stem cell mobilization. Blood Rev (2014) 1.09
Management of paraproteinaemia. Postgrad Med J (2007) 1.08
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. Blood (2005) 1.08
Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc (2016) 1.07
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant (2008) 1.07
Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2012) 1.07
How we manage autologous stem cell transplantation for patients with multiple myeloma. Blood (2014) 1.06
Anti-angiogenesis therapies: their potential in cancer management. Onco Targets Ther (2010) 1.05
Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs (2009) 1.05
Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist (2010) 1.04
Evolving treatment strategies for myeloma. Br J Cancer (2005) 1.04
Multiple myeloma. Curr Probl Cancer (2009) 1.04
Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer (2011) 1.01
Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant (2009) 1.00
Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia (2014) 0.99
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood (2013) 0.98
Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia (2009) 0.98
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma. Leuk Lymphoma (2012) 0.97
Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs (2009) 0.96
Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. Ann Hematol (2010) 0.96
Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood Cancer J (2013) 0.96
Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production. Blood Cancer J (2011) 0.96
Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials. J Clin Oncol (2014) 0.95
Host CD4+CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCT. Blood (2008) 0.95
Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol (2014) 0.95
Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol (2013) 0.95
Therapy-related myeloid malignancies in myeloma. Mediterr J Hematol Infect Dis (2011) 0.95
Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. J Cancer Res Clin Oncol (2004) 0.95
Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant (2010) 0.95
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood (2005) 0.95
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol (2016) 0.94
Myeloma today: Disease definitions and treatment advances. Am J Hematol (2016) 0.94
Quantification of clonal circulating plasma cells in relapsed multiple myeloma. Br J Haematol (2014) 0.94
Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant (2008) 0.93
A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma--NCIC CTG IND.145. Invest New Drugs (2006) 0.93
Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant (2014) 0.93
Advanced prostate cancer--a case for adjuvant differentiation therapy. Nat Rev Urol (2012) 0.93
RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. Blood (2009) 0.92
Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. PLoS One (2013) 0.92
Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood (2014) 0.91
Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplant (2010) 0.91
Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia (2009) 0.91
A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant (2015) 0.91
Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience. J Korean Med Sci (2008) 0.91
Older patients with myeloma derive similar benefit from autologous transplantation. Biol Blood Marrow Transplant (2014) 0.91
Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. Cancer Immunol Immunother (2011) 0.91
Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study. Clin Lymphoma Myeloma Leuk (2010) 0.90
High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients. Cancer (2008) 0.90
Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant (2011) 0.90
Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines. PLoS One (2011) 0.90
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica (2010) 0.90
In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res (2013) 0.89
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol (2004) 5.84
Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med (2008) 5.48
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet (2010) 5.04
Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet (2010) 4.79
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol (2013) 3.75
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet (2005) 3.75
Representation of South Asian people in randomised clinical trials: analysis of trials' data. BMJ (2003) 3.72
The genetic architecture of multiple myeloma. Nat Rev Cancer (2012) 3.71
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol (2013) 3.67
Serum test for assessment of patients with Bence Jones myeloma. Lancet (2003) 3.04
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica (2008) 2.99
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet (2010) 2.96
Dysregulated humoral immunity to nontyphoidal Salmonella in HIV-infected African adults. Science (2010) 2.91
Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res (2006) 2.87
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol (2013) 2.69
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood (2011) 2.69
IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14). Br J Haematol (2008) 2.54
Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. Arch Surg (2007) 2.52
Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology (2004) 2.51
Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. Clin Cancer Res (2013) 2.45
Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry. Proteomics (2004) 2.43
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood (2006) 2.43
Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood (2007) 2.38
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood (2012) 2.38
The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children. J Clin Invest (2008) 2.35
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood (2010) 2.25
Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal (2012) 2.24
Antimyeloma activity of heat shock protein-90 inhibition. Blood (2005) 2.24
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood (2003) 2.23
Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics (2003) 2.17
Optimizing protein stability in vivo. Mol Cell (2009) 2.15
Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol (2011) 2.14
Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. J Clin Oncol (2005) 2.04
Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clin Chem (2009) 1.99
Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. J Clin Oncol (2005) 1.97
Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood (2002) 1.95
Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant (2005) 1.87
RIDDLE immunodeficiency syndrome is linked to defects in 53BP1-mediated DNA damage signaling. Proc Natl Acad Sci U S A (2007) 1.79
The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma (2009) 1.77
Pressure relieving support surfaces (PRESSURE) trial: cost effectiveness analysis. BMJ (2006) 1.75
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol (2011) 1.71
Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol (2011) 1.71
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res (2007) 1.70
Housekeeping proteins: a preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics (2005) 1.69
Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal Salmonella by blood cells in Africans. Proc Natl Acad Sci U S A (2010) 1.68
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood (2010) 1.67
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol (2011) 1.66
Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. EMBO J (2011) 1.65
Polymorphisms in the oxidative stress genes, superoxide dismutase, glutathione peroxidase and catalase and risk of non-Hodgkin's lymphoma. Haematologica (2006) 1.64
Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood (2013) 1.64
Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. Radiology (2014) 1.64
Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantation. Kidney Int (2013) 1.61
The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin Cancer Res (2011) 1.61
Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity. Blood (2003) 1.60
High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leuk Lymphoma (2010) 1.58
Patient risk factors for pressure ulcer development: systematic review. Int J Nurs Stud (2013) 1.55
ETV6/AML1 fusion by FISH in adult acute lymphoblastic leukemia. Leukemia (2002) 1.54
Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res (2003) 1.53
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. Clin Cancer Res (2009) 1.49
Antenatal peer support workers and initiation of breast feeding: cluster randomised controlled trial. BMJ (2009) 1.48
Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma, provided by the analysis of their IGH rearrangements and somatic hypermutation patterns. Br J Haematol (2009) 1.48
Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem (2005) 1.46
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood (2008) 1.45
Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res (2011) 1.44